7-hydroxy-2-(pyridin-4-yl)-4H-chromen-4-one | 663619-95-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-hydroxy-2-(pyridin-4-yl)-4H-chromen-4-one
• 英文别名: 7-hydroxy-2-(4-pyridinyl)-4H-1-benzopyran-4-one；7-hydroxy-2-pyridin-4-ylchromen-4-one
• CAS: 663619-95-2
• 化学式: C₁₄H₉NO₃
• 分子量: 239.23
• InChiKey: ANXXMPBMGXPEGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  间苯二酚 在 盐酸 、 sodium hydroxide 、 zinc(II) chloride 作用下， 以 乙醚 、 乙醇 、 水 为溶剂， 生成 7-hydroxy-2-(pyridin-4-yl)-4H-chromen-4-one
  参考文献：
  名称：

  Inhibitory effect of flavonoids on human glutaminyl cyclase

  摘要：

  Glutaminyl cyclase (QC) plays an important role in the pathogenesis of Alzheimer's disease (AD) and can be a potential target for the development of novel anti-AD agents. However, the study of QC inhibitors are still less. Here, phenol-4' (R1-), C5-OH (R2-) and C7-OH (R3-) modified apigenin derivatives were synthesized as a new class of human QC (hQC) inhibitors. The efficacy investigation of these compounds was performed by spectrophotometric assessment and the structure-activity relationship (SAR) was evaluated. Molecular docking was also carried out to analyze the binding mode of the synthesized flavonoid to the active site of hQC. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.03.064

文献信息

• [EN] INHIBITION OF PHOSPHOINOSITIDE 3-KINASE BETA<br/>[FR] INHIBITION DE LA PHOSPHOINOSITIDE 3-KINASE BETA
  申请人：KINACIA PTY LTD

  公开号：WO2004016607A1

  公开（公告）日：2004-02-26

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase ß, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase ß of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及磷酸肌醇（PI）3-激酶β的选择性抑制剂，以及这些选择性抑制剂在抗血栓治疗中的应用，以及通过检测化合物对PI 3-激酶β的选择性抑制活性来筛选对新型抗血栓治疗有用的化合物的方法。该发明还涉及作为PI 3-激酶抑制剂的新化合物。
• Inhibition Of Phosphoinositide 3-Kinase Beta
  申请人：Jackson Shaun P.

  公开号：US20080319021A1

  公开（公告）日：2008-12-25

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及选择性磷脂酰肌醇（PI）3-激酶β的抑制剂，使用这些选择性抑制剂进行抗血栓治疗的方法，以及通过检测化合物的PI 3-激酶β的选择性抑制活性筛选有用于新抗血栓治疗的化合物的方法。该发明还涉及新型PI 3-激酶抑制剂化合物。
• Inhibition of phsphoinostide 3-dinase beta
  申请人：Jackson P. Shaun

  公开号：US20060276470A1

  公开（公告）日：2006-12-07

  The present invention relates to selective inhibitors of phosphoinositide (PI) 3-kinase β, use of the selective inhibitors in anti-thrombotic therapy, and a method for screening compounds useful for the new anti-thrombotic therapy by detecting selective inhibitory activity of PI 3-kinase β of the compound. The invention also relates to novel compounds that are inhibitors of PI 3-kinase.

  本发明涉及选择性抑制磷脂酰肌醇（PI）3-激酶β的抑制剂，使用这些选择性抑制剂进行抗血栓治疗的方法，以及通过检测化合物的PI 3-激酶β的选择性抑制活性筛选有用于新的抗血栓治疗的化合物的方法。本发明还涉及新的PI 3-激酶抑制剂化合物。
• INHIBITION OF PHSPHOINOSTIDE 3-DINASE BETA
  申请人：Kinacia Pty Ltd.

  公开号：EP1537102A1

  公开（公告）日：2005-06-08
• US7598377B2
  申请人：——

  公开号：US7598377B2

  公开（公告）日：2009-10-06